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Abstract
Background: Long-term b-adrenergic receptor (b-AR) blockade reduces mortality in patients with heart failure. Chronic
sympathetic hyperactivity in heart failure causes sustained b-AR activation, and this can deplete Ca
2+ in endoplasmic
reticulum (ER) leading to ER stress and subsequent apoptosis. We tested the effect of b-AR blockers on ER stress pathway in
experimental model of heart failure.
Methods and Results: ER chaperones were markedly increased in failing hearts of patients with end-stage heart failure. In
Sprague-Dawley rats, cardiac hypertrophy and heart failure was induced by abdominal aortic constriction or isoproterenol
subcutaneous injection. Oral b-AR blockers treatment was performed in therapy groups. Cardiac remodeling and left
ventricular function were analyzed in rats failing hearts. After 4 or 8 weeks of banding, rats developed cardiac hypertrophy
and failure. Cardiac expression of ER chaperones was significantly increased. Similar to the findings above, sustained
isoproterenol infusion for 2 weeks induced cardiac hypertrophy and failure with increased ER chaperones and apoptosis in
hearts. b-AR blockers treatment markedly attenuated these pathological changes and reduced ER stress and apoptosis in
failing hearts. On the other hand, b-AR agonist isoproterenol induced ER stress and apoptosis in cultured cardiomyocytes. b-
AR blockers largely prevented ER stress and protected myocytes against apoptosis. And b-AR blockade significantly
suppressed the overactivation of CaMKII in isoproterenol-stimulated cardiomyocytes and failing hearts in rats.
Conclusions: Our results demonstrated that ER stress occurred in failing hearts and this could be reversed by b-AR blockade.
Alleviation of ER stress may be an important mechanism underlying the therapeutic effect of b-AR blockers on heart failure.
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Introduction
Heart failure remains a leading cause of hospitalization and
death. A number of evidence indicates that the activity of
sympathetic nervous system plays an important role in the
pathogenesis of heart failure[1,2,3]. It has long been recognized
that heart failure patients have higher catecholamine levels in their
blood. Elevated circulating catecholamines result in chronic
b-AR activation in the heart[4]. This has been thought to be a
compensatory reaction to enhance cardiac contractility. Intrigu-
ingly, a number of clinical studies have demonstrated b-AR
blockers as one of the few classes of drugs that improve cardiac
function and reduce mortality in patients with heart failure[4]. But
the mechanisms underlying the therapeutic effects of b-AR
blockers on failing hearts have been poorly understood. One
possible explanation is that b-blockers may compete with the
binding of norepinephrine and epinephrine to their receptors, and
thus attenuates the ‘‘fight or flight’’ reaction of the heart[5]. But it
is unclear how blocking a pathway that is known to increases
contractility of normal hearts can improve the function of failing
hearts. Clearly, the putative mechanism by competing with the
effect of catecholamines on cardiac contractility cannot fully
explain the therapeutic effect of b-AR blockers on failing hearts.
Other mechanisms likely exist. Elucidating these mechanisms will
not only deepen the understanding on b-AR blockers therapy, it
may also lead to new approaches to treat heart failure.
b-AR stimulation by elevated catecholamines activates dual
signaling pathways mediated by the adenylate cyclase-cAMP-
protein kinase A (PKA) and Ca
2+/calmodulin-dependent protein
kinase II (CaMKII)[6]. PKA phosphorylates and activates the
ryanodine receptor RyR2 (sarcoplasmic reticulum Ca
2+ release
channel) [7]. CaMKII modulates an array of key proteins involved
in Ca
2+ handling, such as the sarcoplasmic/endoplasmic reticulum
Ca
2+-ATPase (SERCA) and its regulator, phospholamban (PLB),
ryanodine receptor RyR2, and sarcolemmal L-type Ca
2+ channels
(LCC)[8]. Constant hyperactivation of RyR2 can lead to increased
Ca
2+ release and Ca
2+ leak in myocytes during diastole[9,10]. The
long-term consequence of increased Ca
2+ release and diastolic
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2+ leak from the sarcoplasmic reticulum (SR) is the depletion of
SR Ca
2+ stores[9]. It is well established that Ca
2+ depletion may
induce ER stress[11]. ER stress is a series of adaptive responses in
cells to alleviate the accumulation of unfolded proteins[12].
Normal protein folding requires adequate Ca
2+ concentration in
ER[13]. Ca
2+ depletion, as occurred in failing cardiomyocytes,
renders protein unfolding[13].
It has been reported that endoplasmic reticulum (ER) stress is
involved in many heart diseases that contribute to heart failure at
last, including artherosclerosis, myocardial ischemia, dilated cardio-
myopathy[14,15,16]. The endoplasmic reticulum is a central
organelle of each eukaryotic cell as the place of calcium storage,
lipid synthesis, proteins folding and protein maturation[17].
Disturbances in any of these functions such as excessive accumu-
lation of unfolded protein (unfolded protein response, UPR) or
protein traffic can lead to the so-called ER stress[13]. The
accumulation of unfolded proteins is sensed by three conserved
pathways: IRE1a (inositol-requiring transmembrane kinase and
endonuclease 1a), PERK (protein kinase-like ER kinase), and ATF6
(activation of transcription factor 6)[11]. Activation of these
pathways stimulates an array of designated transcription factors
(such as spliced XBP1, ATF6, and Activating Transcription Factor 4
[ATF4]), which subsequently trigger the expression of UPR-related
genes (such as C/EBP homologous protein [CHOP] and Glucose-
Regulated Protein 78 [GRP78])[12]. While the initial responses of
these signaling pathways aim to assist protein folding, severe or
prolonged ER stress will trigger the signals to apoptosis[13]. CHOP
is an important component that mediates PERK activation-induced
apoptosisinERstress[18].Thec-Jun N-terminalkinase (JNK) isalso
activated in response to ER stress [19]. Indeed, ER stress-induced
apoptosishas been shown to playimportant roles inthe pathogenesis
of diabetes and neurodegenerative disorders[20].
The chronic b-AR hyperactivation causes SR Ca
2+ depletion,
and this likely induces perpetual ER stress responses in failing
heart. We thus hypothesize that ER stress is a critical downstream
event of b-AR signaling pathway and b-AR blockers may protect
cardiomyocytes by relieving ER stress. In the present study, we
examined the hypothesis in cultured cells and animal models as
well as in the human failing hearts. We found that chronic b-AR
activation induces severe ER stress and apoptosis. b-AR blocker
treatment markedly alleviates ER stress responses in vitro and in vivo
leading to reduced hypertrophy and improved cardiac function.
And the effect b-AR blockers on ER stress signaling may be
contributable to inhibition of the CaMKII overactivation and
restoration of the intracellular Ca
2+ balance.
Results
Induction of ER Stress in Human Heart Failure
We collected heart samples from 4 receipts of heart transplan-
tation who suffered from dilated cardiomyopathy with end-stage
heart failure, and 9 patients undergoing mitral valve replacement,
as well as 4 normal hearts of traffic accident victims. The
candidate of patients undergoing mitral valve replacement
presented with heart failure, including symptoms corresponding
to a New York Heart Association (NYHA) class 3–4 heart failure
(mean NYHA class 3.460.5) and left ventricular dilation on
echocardiography (mean left ventricular end-diastolic diameter
57.6610.2 mm at presentation) (Table 1).
We investigated the expression of several molecular indicators of
ER stress in hearts of those patients, including GRP78, PERK,
eIF2a and CHOP. We found significant activation of the PERK to
eIF2a arm of the stress response in hearts from the patients with
heart failure, evaluated by increased phosphorylated eIF2a and
PERK compared with normal hearts (Figure 1A and 1B).
Figure 1A also showed that JNK activity, indicated by c-Jun
phosphorylation, was also significantly elevated in the human
failure hearts. These results indicated that ER stress and its
associated apoptosis signaling pathways appeared to be a general
occurrence in human failing hearts arisen from varying diseases.
b-AR Blockers Attenuated Cardiac Hypertrophy and
Improved the Function of Failing Hearts
To investigate the effect of b-AR blockers on ER stress of failing
hearts in vivo, we first established a cardiac hypertrophy model that
shows cardiac dysfunction at chronic stage by performing an
abdominal aortic constriction (AAC). The animals were divided
into sham, AAC and b-AR blockers treatment groups. AAC-
induced cardiac hypertrophy was assessed by increase of the
ratio of heart weight to tibia length (HW/TL) and heart size.
Metoprolol and propranolol treatments prevented cardiac hyper-
trophy induced by AAC (Figure 2A and 2B). Morphology analyses
also showed that AAC induced a marked time-dependent increase
myocyte hypertrophy, and this was significantly reduced in the
hearts of b-AR blockers-treated rats (Figure 2C).
Detailed examination of heart function was carried out by
invasive pressure-volume analysis. As shown in table 2, cardiac
function in AAC rats was decreased in comparison with that sham
animals as evidenced by the markedly reduced dP/dtmax and dP/
dtmin, and increased left ventricular end diastolic pressure
(LVEDP) and tau (table 2, P,0.01). Contractile function assessed
through dP/dtmax was improved by b-AR blockers as compared
to AAC rats; similar results were observed for diastolic function
(LVEDP, tau and dP/dtmin) (Table. 2, P,0.05). Ventricular
afterload (indexed by Ea, arterial elastance) was identically
elevated by AAC and restored by administration of propranolol
for 4 weeks (Table. 2, P,0.05).
We carried out another animal model of heart failure with
continuous infusion of b-adrenergic agonist isoproterenol (Iso) for
2 weeks, concurrently treated them with metoprolol or vehicle.
Similar results were also observed from these Iso rats. Iso infusion
induced significantly cardiac hypertrophy, and metoprolol treat-
ment blunted the Iso-induced heart hypertrophy (Figure 2D and
2E). The left ventricle function was slightly improved assessed by
invasive pressure-volume analysis (Table. 3). This data suggested
that b-AR blockers attenuated cardiac hypertrophy and improved
heart function in rats of heart failure.
b-AR Blockers Suppressed ER Stress in Hypertrophic and
Failing Hearts of Rats
To explore the effect of b-AR blockers on ER stress in failing
hearts in vivo, we examined the expression of several molecular
indicators of ER stress in hypertrophic and failing hearts of rats.
ER stress responses were seen in the process of cardiac
hypertrophy and heart failure, as assessed by increased expression
of GRP78 and spliced XBP-1 (Figure 3A and 3B). Metoprolol
and propranolol therapy significantly suppressed the ER stress
responses in hypertrophic and failing myocardium.
To further support this notion, we also detected the effect of b-AR
blockers on ER stress process through immunohistochemical analyses.
As shown in Figure 4C,it revealed that the number of GRP78-positive
cells, as well as KDEL -positive cells and CHOP-positive cells was
increased in the hearts of the rats after AAC, and treatment with
metoprolol or propranolol significantly reduced those positive cells.
Similar to the findings above, sustained Iso infusion for 2 weeks
induced marked ER stress in hearts. b-AR blockers treatments
suppressed ER stress responses in Iso-induced hypertrophic and
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importance of increased catecholamines in the onset of ER stress
in cardiac remodeling and failure. Taken together, all evidence
above demonstrated that b-AR blockade alleviated ER stress in
cardiac hypertrophy and heart failure in rats.
b-AR Blockers Suppressed ER Stress-Mediated Apoptosis
in Cardiac Hypertrophy and Failure
We examined CHOP expression in hearts subjected to AAC
with or without b-AR blocker treatment. Results showed that the
expression of CHOP increased dramatically after AAC; and
metoprolol or propranolol treatment abolished expression of
CHOP (Figure 4A and 4B). And treatment with metoprolol
markedly decreased the number of apoptotic cells in the failing
hearts of rats exposed to chronic Iso stimulation (Figure 4C). Thus,
sustained ER stress triggered apoptosis in hypertrophic and failing
hearts induced by either chronic loading stress or b-adrenergic
stimulation, and these could be prevented by b-AR blockade.
b-AR Blockers Reduced ER Stress in Cardiomyocytes
To investigate whether the action of b-AR participate in ER
stress, we pretreated H9c2(2–1) cells with Iso,and found that Iso
significantly increased expression of GRP78 (Figure 5A). To
investigate whether initiation of ER stress induced by b-AR
stimulation is associated with PKA or CaMKII signaling pathway,
we pretreated H9c2(2–1) cells with PKI (a specific inhibitor of
PKA), KN93 (a specific inhibitor of CaMKIId) or propranolol
before exposing them to Iso. Propranolol remarkably decreased
Iso-induced GRP78 overexpression, while PKI, KN93 had no
such significant effect (Figure 5B).
Table 1. Clinical characteristics of patients with mitral valve replacement.
Patient 1 2 3 4 5 6 7 8 9 Summary
Age 43 27 58 63 42 52 45 56 48 48.2610.7
Sex male female female female female female female female female N/A
Diagnosis MI MI MS MS MI, TI MVP MS MVP MS N/A
D i a b e t e s N NNNNNNNNN / A
H y p e r t e n s i o n N NNNNNNNNN / A
A F N NYYNNNNN2 / 9
NYHA 4 3 3 4 3 3 3 4 4 3.460.5
EF 78 66 48 63 56 57 45 55 50 57.6610.2
MI, mitral insufficiency; MS, mitral stenosis; AF, atrial fibrillation; TI, tricuspid insufficiency; MVP, mitral valve prolapse; N/A, not applicable.
doi:10.1371/journal.pone.0027294.t001
Figure 1. Induction of ER Stress in Human Heart Failure. ER stress markers including phosphorylated eIF2a (p-eIF2a), phosphorylated PERK (p-
PERK), GRP78 and CHOP and apoptosis marker phosphorylated c-Jun (p-c-Jun), were examined in the heart samples from patients with heart failure.
(A) ER stress was increased in heart transplant recipients’ failing hearts compared with normal heart. DCM, dilated cardiomyopathy. (B) p1-p9, heart
samples of 9 patients undergoing mitral valve replacement; N1 and N2, normal human hearts. Proteins were normalized to b-actin. *P,0.05 vs.
normal hearts.
doi:10.1371/journal.pone.0027294.g001
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generally, we pretreated H9c2(2–1) cells with different b-AR
blockers, metoprolol and propranolol, before exposing them to
tunicamycin (TM) or thapsigargin (TG), agents commonly used to
induce ER stress. Metoprolol and propranolol both significantly
decreased TG or TM-induced GRP78 overexpression, especially,
propranolol almost completely inhibited the TG-induced GRP78
activation after 24 hours incubation (Figure 5C). These results
suggested that b-AR blockers reduced ER stress induced by
different stressors in cells.
b-AR Blockers Protected Cardiomyocytes against ER
Stress-Mediated Apoptosis
Severe or prolonged ER stress triggers apoptosis. The
characteristic markers of ER stress-induced apoptosis are c-Jun
N-terminal kinase (JNK) and caspase-12 activation. As shown in
Figure 2. b-AR blockers attenuated cardiac hypertrophy and improved the function of failing hearts. (A) to (C) showed b-AR blockers
attenuated cardiac hypertrophy in rats induced by abdominal aortic constriction (AAC). (A) Representative images of hearts. Scale, 5 mm. (B) Ratio of
heart weight to body weight. *P,0.05 vs. sham. (C) HE staining of rat hearts and cardiomyocyte cross-sectional diameter (mm). Scale bar, 50 mm.
*P,0.05 vs. sham, #P,0.05 vs. AAC. (D) and (E) showed b-AR blocker attenuated Iso-induced cardiac hypertrophy in rats. (D) Ratio of heart weight to
body weight. *P,0.05 vs. control. (E) HE staining of rat hearts and cardiomyocyte cross-sectional diameter (mm). Scale bar, 50 mm. Iso, isoproterenol.
*P,0.05 vs. control, #P,0.05 vs. Iso.
doi:10.1371/journal.pone.0027294.g002
Table 2. Hemodynamic parameters in AAC rats and AAC rats with b-AR blocker treatment.
Sham AAC AAC+Meto-4w AAC+ Prop-4w AAC+Meto-8w AAC+ Prop-8w
N 655 4 8 6
HR 189.369.9 195.6619.4 208.8628.5 200.5623.2 202.6621.3 207.5611.5
LVEDP 0.463.3 4.962.6* 0.561.9{ 25.262.7{ 8.163.1 563.1
Ea 1.4560.85 2.1960.7* 1.9061.40 1.260.4{ 1.7061.20 1.5460.4
dPdtMax 651661211 44486876* 51476627 656661401{ 616961568{ 675261064{
dPdtMin 2721161820 250606940* 2607762152 2805462463{ 2726061839{ 2748061507{
tauWeiss 14.362.8 17.962.3* 16.462.2 13.761.4{ 2264.6 17.561.4
HR, heart rate; LVEDP, left ventricular end diastolic pressure; Ea, arterial elastance; dP/dtmax, maximal slope of systolic pressure increment; dP/dt min maximal slope of
diastolic pressure decrement; meto, metoprolol; prop, propranolol. Data are mean 6 s.d. * P,0.05 versus control; {P,0.05 vs. AAC.
doi:10.1371/journal.pone.0027294.t002
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cleavage in H9c2 cells treated by TG or TM, and propranolol had
the stronger effect which nearly blocked the activation of caspase-
12. In accordance with results above, pretreatment of the cells with
metoprolol or propranolol significantly reduced cell apoptosis
induced by TG or TM as determined by Hoechst staining
(Figure 6B and 6C) and Annexin V-FITC binding with flow
cytometry analysis (Figure 6D). These results indicated that b-AR
blockade reduced ER stress responses and subsequent apoptosis in
cardiomyocytes.
b-AR Blockers Suppressed Overactivation of Calmodulin
Kinase II in Rat Failing Hearts
We pretreated H9c2(2–1) cells with KN93 or more selective
b1-blocker metoprolol before exposing them to TM. Figure 7A
showed specific inhibition of CaMKIId with KN93 did not
suppress the ER stress, while metoprolol alleviated ER stress
assessed by decreased expression of GRP78, phosphorylated
PERK and CHOP. We assessed activation of CaMKII in rats
failing hearts. As showed in Figure 7B, CaMKII significant
Table 3. Hemodynamic parameters in Iso rats and Iso rats
with b-AR blocker treatment.
Control Iso Iso+meto
N5 4 5
HR (bpm) 228.3622.7 217.5623.4 189.0616.5
Pes (mmHg) 136.9615.8 136.7613.1 163.4649.9
Ped (mmHg) 2.867.2 4.066.8 14.667.8
dP/dtmax (mmHg/s) 813461088 59336800* 630561406
dP/dtmin (mmHg/s) 27521.36605 2542561912* 2503362190
HR, heart rate; PES, end-systolic pressure; PED, end-diastolic pressure; dP/dtmax,
maximal slope of systolic pressure increment; dP/dt min maximal slope of
diastolic pressure decrement; Iso, isoproterenol; meto, metoprolol. Data are
mean 6 s.d. *P,0.05 vs. control.
doi:10.1371/journal.pone.0027294.t003
Figure 3. b-AR blockers suppressed ER stress in hypertrophic and failing hearts of rats. (A) ER chaperone GRP78 and spliced XBP-1 were
increased in AAC rats (1or 4 or 8 weeks after operation), and metoprolol treatment (30 mg/kg/d for 8 weeks) reduced the epression of GRP78 and
spliced XBP-1. Proteins were normalized to b-actin. (B) GRP78 was increased in AAC rats (4 weeks), and propranolol treatment (30 mg/kg/d for 4
weeks) reduced the epression of GRP78. Protein was normalized to b-actin. (C) Immunohistochemical analyses of rats’ hearts and number of GRP78,
KDEL and CHOP-positive cells per mm
2. Scale bar, 40 mm. For (A) to (C), *P,0.05 vs. sham, #P,0.05 vs. AAC. (D) GRP78 and spliced XBP-1 was
increased in Iso rats, and metoprolol treatment (30 mg/kg/d for 2 weeks) reduced the epression of GRP78 and spliced XBP-1. Proteins were
normalized to b-actin. *P,0.05 vs. control, #P,0.05 vs. Iso.
doi:10.1371/journal.pone.0027294.g003
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lated CaMKII compared with normal hearts. And administration
of metoprolol could suppress the overactivation of CaMKII.
Taken together, these results suggest that b-AR blockade
decreased overactivation of CaMKII, which could decrease
intracellular Ca
2+ and suppress ER stress.
Materials and Methods
Materials
Metoprolol, propranolol, thapsigargin (TG), tunicamycin (TM),
isoproterenol (Iso), KN-93 were purchased from Sigma-Aldrich
(St. Louis, MO). Antibodies for phosphorylated PERK, PERK,
phosphorylated eIF2a, JNK1, phospho-c-Jun (p-Ser73), GRP78,
CHOP (GADD153), KDEL receptor, XBP1, phosphorylated
CaMKIId, CaMKIId, b-actin and PKI (6–22) were from Santa
Cruz Biotechnology (Santa Cruz, CA). Antibody for caspase-12
was from Chemicon (Millipore, Billerica, MA). Horseradish
peroxidase-conjugated secondary antibodies (goat anti-rabbit
immunoglobulin G and rabbit anti-mouse immunoglobulin G)
and enhanced chemiluminescence reagents were from Pierce
Biotechnology (now part of Thermo Fisher Scientific, Rockford,
IL). Polyvinylidene difluoride (PVDF) membranes were from
Whatman (now part of GE Healthcare Life Sciences, Buck-
inghamshire, UK). Hoechst 33258 was from Calbiochem (part of
Merck KGaA, Darmstadt, Germany) and Annexin V-FITC
apoptosis detection kit and TACSTM TdT Kit apoptosis
detection kit were from R&D (Minneapolis, MN). All other
reagents were purchased from commercial suppliers unless
otherwise specified.
Cell Culture
H9c2(2–1) cells, a subclone of the original clonal cell line
derived from embryonic BD1X rat heart tissue, were obtained
from American Type Culture Collection (CRL-1446) and cultured
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) and penicillin-streptomycin
(100 IU/ml) in a humidified atmosphere of 95% air and 5% CO
2
at 37uC.
Animals
Male Sprague-Dawley rats (150–200 g) were obtained from the
Experimental Animal Center of Tongji Medical College (Wuhan,
People’s Republic of China). All animal experimental protocols
complied with the ‘‘Guide for the Care and Use of Laboratory
Animals’’ published by the United States National Institutes of
Health. The study was approved by the Institutional Animal
Research Committee of Tongji Medical College (permit number:
SYXK 2004–0028). All animals were housed at the animal care
facility of Tongji Medical College at 25uC with 12/12-h light/dark
cycles and allowed free access to normal rat chow and water
throughout the study period. Rats were randomly assigned to
different treatment groups.
Figure 4. b-AR blockers suppressed ER stress-mediated apoptosis in cardiac hypertrophy and failure. (A) and (B) CHOP was increased in
AAC rats (4 or 8 weeks after operation), and metoprolol (30 mg/kg/d for 4 or 8 weeks)or propranolol (30 mg/kg/d for 4 or 8 weeks) treatment
reduced expression of CHOP. CHOP was normalized to b-actin. (C) Representative images of TUNEL showing cardiac myocytes apoptosis and
quantitative analysis of TUNEL-positive myocardial cells in rats. Nuclei of normal cells are blue, and nuclei of apoptosis cells (TUNEL-positive cells) are
brown.
doi:10.1371/journal.pone.0027294.g004
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Pressure overload was induced by abdominal aorta constriction
(AAC) in male Sprague Dawley rats according to the method
described previously[21]. 80 rats were randomly assigned to one of
4 experimental groups: In group 1 (n=20), sham-operated
animals served as controls. In group 2 (n=20), cardiac
hypertrophy and heart failure was induced by abdominal aorta
constriction (AAC) without further treatment. In group 3 (n=20),
AAC was performed and treatment with metoprolol for 4 or 8
weeks at a dose of 30 mg/kg/day in saline after operation as
described previously[22]. In group 4 (n=20), AAC was performed
and treatment with propranolol for 4 or 8 weeks at a dose of
30 mg/kg/day in saline after operation.
Sustained b-adrenergic stimulation can be induced by low dose
of isoproterenol (Iso) subcutaneous injection as reported be-
fore[23]. 48 rats were randomly divided in 3 groups: In group 1
(n=16), rats were administered with saline subcutaneously per day
as control. In group 2 (n=16), rats were administered with Iso in
saline subcutaneously 5 mg/kg/d for 2 weeks. In group 3 (n=16),
treatment with metoprolol in saline at a dose of 30 mg/kg/d was
started when rats were exposing to Iso for 2 weeks.
Abdominal Aorta Constriction
Cardiac hypertrophy and heart failure was induced by AAC
according to the method described previously[21]. Briefly, rats
were anesthetized with pentobarbital sodium at a dose of 40
mg/kg body weight intraperitoneally. Once anaesthesia is induced,
it can be maintained by using a nose cone of halothane. The animal
should be carefully monitored from the point of view of body
temperature, respiratory rate, circulation, airway problems and
Figure 5. b-AR blockers alleviated ER stress induced in cardiomyocytes. (A) Iso increased GRP78 in a dose-dependent manner in H9c2(2–1)
cells. *P,0.05 vs. control (B) Propranolol reduced Iso induced-ER Stress in H9c2(2–1) cells. Cells were pretreated with PKI (specific inhibitor of PKA,
5 mmol/L), KN-93 (specific inhibitor of CaMKIId, 0.5 mmol/L), metoprolol (meto, 10 mmol/L) or propranolol (prop, 10 mmol/L) for 1 hour, and exposed
to Iso (10 mmol/L) for 24 hours. Cell lysates were then immunoblotted for GRP78, normalized to b-actin as a loading control. Iso, isoproterenol.
*P,0.05 vs. control, #P,0.05 vs. Iso. (C) b-AR blockers blocked ER stress induced by TG or TM. Cells were treated with TG (5 mmol/L) or TM (5 mg/ml)
with or without metoprolol (10 mmol/L) or propranolol (10 mmol/L) for 24 hours. Cell lysates were then immunoblotted for GRP78, normalized to b-
actin. dmso, cell with vehicle dissolvant dimethyl sulphoxide; TG, thapsigargin; TM, tunicamycin. *P,0.05 vs. control, #P,0.05 vs. TM, & P,0.05 vs.
TG.
doi:10.1371/journal.pone.0027294.g005
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then the retroperitoneum was entered at 2 cm left lumbar
vertebrae under the costal arch through a small incision. The
abdominal aorta was isolated upper the renal artery crotch and
constricted by a 4–0 silk suture ligature tied against a 22-gauge
needle. The needle was removed to form a constriction of 0.7 mm
in diameter. Sham-operated rats underwent a similar surgical
procedure without aorta constriction. The animals were divided
into sham receiving oral administration of saline, AAC rats with
just saline as control, and treatment groups. In treatment groups,
animals were received b-AR blocker metoprolol or propranolol for
4 or 8 weeks at a dose of 30 mg/kg/day in saline after operation as
described previously[22].
In vivo Hemodynamics
In vivo LV function was assessed by Millar PV catheter as
described previously[24]. Rats were anesthetized as described
above and placed on heating pads with core temperature
maintained at 37uC. A microtip pressurevolume catheter (SPR-
838; Millar Instruments, Houston, TX) was inserted into the right
carotid artery and advanced into the left ventricle (LV) under
pressure control. After stabilization for 20 min, the signals were
continuously recorded at a sampling rate of 1,000/s using an
ARIA pressure-volume conductance system (Millar Instruments)
coupled to a Powerlab/4SP analog-to-digital converter (AD
Instruments, Mountain View, CA) and a personal computer. All
pressure-volume loop data were analyzed using a cardiac pressure-
volume analysis program (PVAN3.6; Millar Instruments), and
HR, LV end-systolic pressure (PES), LV end-diastolic pressure
(PED), left ventricular end diastolic pressure (LVEDP), left
ventricular end systolic pressure (LVESP), arterial elastance (Ea),
tauWeiss, maximal slope of systolic pressure increment (dP/dt
max) and diastolic pressure decrement (dP/dt min) were computed
as described previously[25,26].
Human Heart Samples
This study was approved by the Review Board of Tongji
Hospital and Tongji Medical College. The subjects recruited to
the study provided written informed consent. The investigation
conforms to the principles outlined in the Declaration of Helsinki.
Tissue samples were obtained and kept frozen in liquid nitrogen
and then stored at 280uC until use.
Histochemical Analysis
Formalin fixed hearts were embedded in paraffin, sectioned into
4 mm slices, and stained with H&E. In order to determine the
expression of ER stress chaperons, KDEL receptors were detected
by immunohistochemical staining of formalin-fixed and paraffin-
embedded heart sections. Briefly, after deparaffinization and
rehydration, slides were incubated in 3% hydrogen peroxide for
10 min, PBS containing 10% of goat serum for 30 min and with a
primary antibody to KDEL (overnight incubation at 4uC). After
washing, sections were stained with a secondary biotinylated anti-
rabbit antibody (Vector, CA) (room temperature; 30 min), followed
by streptavidin-peroxidase (DakoCytomation, Denmark) (room
temperature; 30 min). Subsequently the slides were incubated in
DAB chromogen for 5 min at room temperature. Then the sections
were counterstained with hematoxylin, and coverslipped.
Figure 6. b-AR blockers protected cardiomyocytes against ER stress-mediated apoptosis. (A) b-AR blockers suppressed activation of
caspase-12 in H9c2(2–1) cells. Cells were treated with TG (5 mmol/L) or TM (5 mg/ml) with or without metoprolol (10 mmol/L) or propranolol (10 mmol/L)
for 12 hours. Cell lysates were then immunoblotted for caspase-12. Caspase-12 cleavage was normalized to b-actin. *P,0.05 vs. control, #P,0.05 vs.
TM, & P,0.05 vs. TG. (B) and (C) Hochst-positive cells (%). H9c(2–1) cells were pretreated with metoprolol (10 mmol/L, 1 h) or propranolol (10 mmol/L,
1 h), then exposed to TG (5 mmol/L, 24 h) or TM (5 mg/ml, 24 h) before staining with Hochst33258 as indicated. Hochst-positive cells are expressed as a
percentageofthenumberoftotalcells.**P,0.001vs. control. # P,0.05vs. TGorTM.(D)AnexinV-positivecells (%). H9c(2–1) cellswerepretreatedwith
metoprolol (10 mmol/L, 1 h) or propranolol (10 mmol/L, 1 h), then exposed to TG (5 mmol/L, 24 h) before staining with Anexin V/PI as indicated. Analyze
by flow cytometry immediately after incubation. Anexin V-positive cells are expressed as a percentage of the number of total cells. *P,0.05 vs. control.
#P,0.05 vs. TG.
doi:10.1371/journal.pone.0027294.g006
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Imagic Analysis System developed by the Ultrastructural Pathol-
ogy Department of Tongji Hospital. Cardiac myocyte cross-
sectional diameter and KDEL-positive cells per 1 mm
2 were
measured. The distance across the myocardial cell at its narrowest
plane across the nucleus was measured in 75 cells from each LV
(25 from the epicardium, 25 from the myocardium, and 25 from
the endocardium). The mean diameter was calculated for the LV
in each animal. We counted the number of KDEL positive cells
(brown staining) per mm
2 for 5 different visual fields in each
animal, and the average number was calculated in each animal
and each group.
Apoptosis Detection
Hoechst Staining. Hoechst33258 suspended in dH2Oa ta
1 mM concentration was prepared as stock solution. Cultured cells
were suspended at approximately 1–2610
6/ml in buffered media
(pH 7.2). Hoechst33258 dye was added to cell suspension to
10 mmol/L final concentrations, and incubated at 37uC for 30
minutes. The cells then were observed under fluorescence
microscope or analyzed by flow cytometry immediately.
Hoechst33258 stained cells were illuminated with an argon laser
tuned for UV (346–352 nm) and resulting fluorescence were
detected at 460 nm.
Annexin V-FITC Apoptosis Assay. The cultured cells were
gently trypsinized and washed with serum-containing media. After
centrifugation, cell pellets (1–5610
5 cells) were resuspended in
500 ml of 1x Binding Buffer, and 5 ml of Annexin V-FITC and 5 ml
of propidium iodide (PI 50 mg/ml) were added. Annexin V-FITC
binding was analyzed by flow cytometry (Ex =488 nm; Em =
530 nm) using FITC signal detector (usually FL1) and PI staining
by the phycoerythrin emission signal detector (usually FL2)
immediately after 5 min incubation at room temperature in the
dark.
TUNEL. Terminal deoxynucleotidyl transferase–mediated
dUTP nick-end labeling (TUNEL) reaction was performed by
using the TACSTM TdT Kit apoptosis detection kits (R&D).
Immunoblotting
Cell lysates and lysates from heart tissues, prepared as
previously described[27], were matched for protein concentration,
separated on SDS polyacrynamide gels (8–12%) and transferred to
nitrocellulose membranes. Next, the membranes were blocked
with 5% nonfat milk and 3% BSA for 2 hour and incubated
overnight with primary antibodies as indicated. The following day,
membranes were washed three times and incubated with
appropriate secondary antibody for 2 hour at room temperature.
Antibody binding was detected by enhanced chemiluminescence.
Statistical Analysis
All values are expressed as mean 6 s.e. unless noted otherwise.
Differences between data groups were evaluated for significance
using Student t-test of unpaired data or one-way analysis of
variance (ANOVA) and Bonferroni post-test. P,0.05 was
accepted as statistically significant.
Discussion
In the present study, we identify long-term oral b-AR blockers
suppresses ER stress in cardiac hypertrophy and heart failure. We
Figure 7. b-AR blockers suppressed overactivation of Calmodulin Kinase II in rat failing hearts. (A) Metoprolol alleviated ER stress and
overactivation of CaMKII induced by tunicamycin (TM). Cells were pretreated with KN93 (KN, 0.5 mmol/L or 2 mmol/L), metoprolol (M, 10 mmol/L or
20 mmol/L) for 1 hour, and exposed to TM (5 mg/ml) for 24 hours. Cell lysates were then immunoblotted for phosphorylated CaMKII, phosphorylated
PERK, GRP78 and CHOP, which were all normalized to b-actin. *P,0.05 vs. control, #P,0.05 vs. TM. (B) Metoprolol suppressed the overactivation of
CaMKII in AAC rats. *P,0.05 vs. sham, #P,0.05 vs. AAC.
doi:10.1371/journal.pone.0027294.g007
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human failing hearts. The similar result was subsequently found in
isoproterenol-stimulated cardiomyocytes and rat models of heart
failure after abdominal aortic constriction and isoproterenol
subcutaneous injection. b-AR blockers treatment reduced ER
stress and associated apoptosis in cardiomyocytes and rats failing
hearts. This effect may be attributable to prevention of CaMKII
overactivation and restoration of intracellular Ca
2+ balance.
Heart failure (HF) is a complex clinical syndrome that involves a
series of responses in the heart, neural and hormonal systems, and
vasculature[28]. It has been documented that ER stress is involved
in cardiotoxicity and heart diseases that eventually may evolve into
heart failure[14,15,16]. For instance, imatinib, the causal agent in
chronic myelogenous leukemia, exhibit cardiotoxicity; and the
underlying mechanism seems to be related to the ER stress caused
by this drug[29]. ER can generate and propagate apoptotic signals
in response to myocardial ischemic stress[15,30]. Pressure
overload by transverse aortic constriction induces expression of
ER chaperones and ER stress-induced apoptosis of cardiac
myocytes, leading to cardiac hypertrophy and heart failure[14].
Okada and his colleage found ER stress induced in patients with
dilated cardiomyopathyv (DCM) and adriamycin cardiomyopa-
thy[14]. In the present study, we found upregulation of ER
chaperones in patients with end-stage heart failure, who received
heart transplantation and mitral valve replacement. We detected
the activation of several ER stress-associated pro-apoptotic
signaling pathways, including PERK, eIF2a, CHOP and JNK,
in human failing hearts. These results confirmed previous studies
and indicated that prolonged ER stress and associated apoptosis
appeared to be a general occurrence in human failing hearts arisen
from varying diseases.
While previous studies implicated ER stress induced in heart
failure, how ER stress is initiated in failing hearts is still unknown.
Our present studies suggest that b-AR hyperactivation may be an
important mechanism underlying ER stress in cardiac hypertro-
phy and failure. Sympathetic nervous system activity plays a
central role in the pathogenesis of heart failure. Catecholamines
are released from the sympathetic nervous system as a result of
increased workload from pressure or volume overload[31]. The
sustained increase in adrenoceptor activity initiates impairment in
b-AR signaling pathway[32]. The identified important down-
stream effect of altered b-AR signaling in heart failure include
hyperposphorylation of LTCC, the NCX, and cardiac ryanodine
receptors[9,33]. Chronic PKA hyperphosphorylation of RyR2 in
heart failure leads to depletion of calcium in SR, which in turn
reduces EC coupling gain and contributes to impaired systolic
contractility[9,10]. On the other hand, Ca
2+ storage and signaling,
as well as the folding, modifying and sorting of newly synthesized
proteins, are among the main functions of the ER in mammalian
cells[11]. Disturbances in any of these functions can result in ER
stress[13]. Both Ca
2+ overload and depletion of the ER Ca
2+ pool
can lead to changes in protein folding and in ER stress[11].
Indeed, we detected strong ER stress response in isoproterenol-
stimulated cardiomyocytes and the hearts of rats subjected to
constant b-AR stimulation. While these initial responses may be
adaptive, prolonged ER stress triggers apoptotic signaling. Parallel
to the activation of ER stress signaling pathways, apoptosis and
loss of heart function were seen in cardiac hypertrophy and failure.
These findings suggest that ER stress maybe a crucial downstream
event of chronic b-AR hyperactivation and ER-induced apoptosis
may be important cause of the loss of cardiac function in heart
failure.
b-AR blockade is one of the most effective treatments with
improving cardiac function and prolonging life in patients with
heart failure[4]. However, the use of b-AR blockers in patients
with heart failure is counterintuitive, because they decrease
contractility acutely in normal and failing hearts. Current
understanding on the mechanism of b-AR blockers therapy
includes the attenuation of chronic hyperactivity of the
sympathetic nervous system[5]. However, this does not fully
explain the beneficial effect of b-AR blockers on failing hearts.
The present study suggested that alleviation of ER stress may
contribute to the action of b-AR blockers. In cultured
cardiomyocytes, b-AR blockers prevented isoproterenol-induced
ER stress responses. Furthermore, experimental therapies with b-
AR blockers also attenuated ER stress reactions in hypertrophic
and failing rat hearts. Corresponding to the attenuation of ER
stress, pro-apoptotic signaling and the number of apoptotic cells
were all diminished by b-AR blockers treatment. The preventa-
tive effect of b-AR blockers on ER stress is also parallel to the
reduction of cardiac hypertrophy and improvement of cardiac
function.
Moreover, the effect of nonselectived b-AR blocker propranolol
on suppressing ER stress seemed stronger than selectived b1-AR
blocker metoprolol. Previous study have ever indicated that
propranolol treatment attenuates LVH by a mechanism unrelated
to its b-adrenoceptor blocking activity, and is possibly mediated
through the known membrane stabilizing effect of this agent[21].
Consider with metoprolol and propranolol had the same effect on
b-AR blocking activity[22], our data above also suggested that the
effect of propranolol on suppressing ER stress may be independent
of its b blockade. Taken together, all lines of evidence indicate that
the therapeutic effect of the b-AR blockers on heart failure may
be, at least partially, attributed to their ability to counteract ER
stress.
How exactly b-AR blockers prevent ER stress responses
remains to be determined. One plausible explanation is that the
administration of b-AR blockers reduces the chronic hyperactivity
of the sympathetic nervous system. Deceased plasma levels of
circulating catecholamines reduce intracellular cAMP levels, and
thus reverse PKA hyperphosphorylation of RyR2[10,34]. This
may restore normal intracellular Ca
2+ handling and Ca
2+ signaling
in failing heart. However, b-AR blockers also dramatically
attenuated ER stress induced by TG and TM, which directly
perturb ER Ca
2+ homeostasis and protein glycosylation. ER stress
induced by these two means is independent of b-AR activation.
The fact that b-AR blockers attenuated ER stress induced by
adrenergic stimulation independent means is a strong indication
that b-AR blockers can alleviate ER stress by mechanisms
independent of b-AR blockade.
Acute b1-adrenergic receptor (b1AR) stimulation activates the
classic Gs-adenylyl cyclase (AC)-cAMP-PKA signaling pathway,
whereas chronic stimulation of b1AR that induces myocyte
hypertrophy and apoptosis requires activation of CaMKII[6,35].
However, inhibition of PKA could not alleviate ER stress. It
revealed that chronic b-adrenergic stimulation induced-ER stress
may be independent of the typical PKA pathway. Increased
activitation of CaMKII, a Ca
2+- dependent kinase, elevates
intracellular Ca
2+. Previous studies[36,37] have demonstrated
that increase of intracellular Ca
2+ was a common mechanism for
aberrant ER stress and unfolded protein response activation. We
found significant activation of CaMKII in isoproterenol-stimulated
cardiomyocytes and rats failing hearts. And b-AR blockade
suppressed overactivation of CaMKII, which could decrease
intracellular Ca
2+ and suppress ER stress. We suppose that effect
of b-AR blockers on ER stress signaling may be contributable to
inhibition of the CaMKII overactivation and restoration of the
intracellular Ca
2+ balance.
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PLoS ONE | www.plosone.org 10 November 2011 | Volume 6 | Issue 11 | e27294In summary, we demonstrated that ER stress is a crucial
downstream event of b-AR hyperactivation in cultured cells and
heart failure in vivo. b-AR blockade markedly relieved ER stress
and ER mediated-apoptosis in cardiomyocytes and hypertrophic
and failing hearts. Thus, alleviation of ER stress may be an
important mechanism underlying the therapeutic effect of b-AR
blockers on heart failure. Preventing or alleviating ER stress may
represent a new approach to treat cardiac hypertrophy and heart
failure.
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